Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS

Adelaida Castillo, Julien Dubois, Ryan M. Field, Frank A. Fishburn, Andrew Gundran, Wilson C. Ho, Sami Jawhar, Julian Kates‐Harbeck, Zahra M. Aghajan, Naomi Miller, Katherine L. Perdue, Jake Phillips, Wesley C. Ryan, Mahdi Shafiei, Felix Scholkmann, Moriah TaylorScientific 2023 · DOI

TL;DR

This study demonstrates the feasibility of using time-domain functional near-infrared spectroscopy (TD-fNIRS) in a clinical setting to measure acute brain and physiological changes induced by subanesthetic ketamine. The findings reveal that ketamine alters cerebrovascular hemodynamics, reducing brain-wide low-frequency fluctuations and prefrontal connectivity, and suggest that these neural and physiological changes, combined with subjective experiences, could serve as biomarkers for treatment outcomes.

What Problem Does This Paper Address?

Understanding the acute effects of psychedelic substances like ketamine on brain activity is crucial for developing personalized treatments for conditions such as depression. However, existing neuroimaging studies often face challenges with scalability, cost, and consistency in methodology, making it difficult to establish reliable biomarkers. This paper addresses the need for a more accessible and scalable neuroimaging technique that can be used in clinical settings to investigate these effects. Specifically, it aims to quantify the cerebrovascular hemodynamic changes induced by subanesthetic ketamine in healthy individuals and explore the relationship between these neural and physiological changes and subjective experiences.

Methods

The study employed a single-blind, placebo-controlled, within-subject design with 15 healthy participants. They received either subanesthetic ketamine (0.75 mg/kg) or a saline placebo via intramuscular injection. The core methodology involved using a novel, portable, whole-head time-domain functional near-infrared spectroscopy (TD-fNIRS) system (Kernel Flow1) to measure brain dynamics. This system captures distributions of photon times of flight, allowing for the estimation of absolute chromophore concentrations (oxy- and deoxy-hemoglobin).

In addition to TD-fNIRS, physiological sensors were used to record pulse rate (PR), pulse rate variability (PRV), electrodermal activity (EDA), and end-tidal CO2. The study analyzed:

  • Cerebrovascular Hemodynamics: Changes in absolute oxy- and deoxy-hemoglobin concentrations.
  • Systemic Physiology: Pulse rate, pulse rate variability, and electrodermal activity.
  • Neural Activity: Fractional Amplitude of Low-Frequency Fluctuations (fALFF) as a proxy for local neuronal activity, derived from the hemodynamic signals.
  • Functional Connectivity: Global brain connectivity (GBC) of the prefrontal cortex, calculated from channel-space connectivity matrices.

The researchers also used validated surveys to assess subjective experiences, including mystical experiences and depressive symptomatology.

Datasets

The study utilized data collected from 15 healthy human participants. No external datasets were used for training or evaluation. The study generated its own dataset of TD-fNIRS and physiological recordings during ketamine and placebo administration.

Key Insights and Ideas

  • TD-fNIRS as a Clinical Tool: The study successfully demonstrates the feasibility and utility of TD-fNIRS for measuring acute neurophysiological effects of psychoactive substances in a clinical setting, offering a scalable alternative to fMRI.
  • Ketamine's Brain-Wide Impact: Ketamine administration led to a significant, brain-wide reduction in fALFF, suggesting a broad impact on local neuronal activity. This finding is particularly interesting given that fALFF alterations are implicated in depression.
  • Prefrontal Connectivity Reduction: A notable finding was the acute decrease in global brain connectivity of the prefrontal cortex following ketamine. This contrasts with some previous fMRI studies suggesting increased connectivity, highlighting the need for further investigation and potentially different sensitivities of TD-fNIRS.
  • Neural-Physiological Link: The study provides preliminary evidence that a combination of neural (fALFF) and physiological (PR) metrics can predict the intensity of subjective mystical experiences. This suggests that these objective measures might serve as biomarkers for treatment response.
  • Subjective Experience Timing: The predicted time-course of mystical experiences, derived from the neural and physiological data, appeared to align with expected pharmacokinetic profiles, suggesting that these objective measures can capture the temporal dynamics of subjective effects.

Key Results

  • Physiological Changes: Ketamine administration resulted in a significant increase in pulse rate (82%) and a significant decrease in pulse rate variability (91%) compared to placebo. Electrodermal activity also significantly increased.
  • Hemodynamic Changes: Ketamine led to a significant increase in oxy-hemoglobin (HbO) and a significant decrease in deoxy-hemoglobin (HbR) during the dosing session compared to saline.
  • fALFF Reduction: Whole-brain fALFF was significantly reduced in the second half of ketamine dosing sessions compared to saline sessions for both HbO and HbR.
  • Global Brain Connectivity: Ketamine acutely reduced prefrontal global brain connectivity (GBC) compared to saline, with a significant reduction observed for HbO and a trend for HbR.
  • Predictive Power: A linear regression model using time-varying fALFF and PR was able to predict participants' RMEQ (Revised Mystical Experience Questionnaire) scores with a mean squared error of 1.77±0.44 and an r-squared of 0.24 on the validation set, performing significantly above chance.
  • Depressive Symptom Link: A GEE model revealed that the interaction between session type (ketamine vs. saline) and fALFF (high or low) was a significant factor in the change in QIDS (Quick Inventory of Depressive Symptomatology) scores, indicating that higher fALFF was associated with a larger reduction in depressive symptoms after ketamine.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small Sample Size: The study involved only 15 healthy participants, which limits the generalizability of the findings, especially to patient populations.
  • Healthy Volunteers: The results may not directly apply to individuals with depression, for whom ketamine is primarily used as a treatment.
  • Single-Blind Design: While participants were blinded to the drug, the potent subjective effects of ketamine likely led to unblinding for most participants after the first dosing session.
  • Fixed Session Order: The study used a fixed order (saline first, then ketamine), which could introduce order effects.
  • Cortical Connectivity Focus: The TD-fNIRS system used provided whole-head coverage, but the connectivity analysis focused primarily on the prefrontal cortex.
  • Technical Limitations: Imperfect head coupling and registration across participants in the TD-fNIRS system may have affected statistical power.

Future work suggested includes:

  • Larger Scale Studies: Conducting larger, longitudinal studies with patient populations to establish robust biomarkers.
  • Combining Modalities: Integrating TD-fNIRS with other neuroimaging techniques like EEG to gain a more comprehensive understanding of brain activity.
  • Exploring Delayed Effects: Investigating the delayed effects of ketamine, as significant neural and psychological changes can occur after the acute phase.
  • Clinical Translation: Further exploring the potential of combined neural and physiological features as therapeutically relevant biomarkers for predicting treatment outcomes in patients.

Summary updated

Abstract

Quantifying neural activity in natural conditions (i.e. conditions comparable to the standard clinical patient experience) during the administration of psychedelics may further our scientific understanding of the effects and mechanisms of action. This data may facilitate the discovery of novel biomarkers enabling more personalized treatments and improved patient outcomes. In this single-blind, placebo-controlled study with a non-randomized design, we use time-domain functional near-infrared spectroscopy (TD-fNIRS) to measure acute brain dynamics after intramuscular subanesthetic ketamine (0.75 mg/kg) and placebo (saline) administration in healthy participants (n = 15, 8 females, 7 males, age 32.4 ± 7.5 years) in a clinical setting. We found that the ketamine administration caused an altered state of consciousness and changes in systemic physiology (e.g. increase in pulse rate and electrodermal activity). Furthermore, ketamine led to a brain-wide reduction in the fractional amplitude of low frequency fluctuations, and a decrease in the global brain connectivity of the prefrontal region. Lastly, we provide preliminary evidence that a combination of neural and physiological metrics may serve as predictors of subjective mystical experiences and reductions in depressive symptomatology. Overall, our study demonstrated the successful application of fNIRS neuroimaging to study the physiological effects of the psychoactive substance ketamine in humans, and can be regarded as an important step toward larger scale clinical fNIRS studies that can quantify the impact of psychedelics on the brain in standard clinical settings.
BibTeX
@inproceedings{castillo2023measuring,
  author = {Adelaida Castillo and Julien Dubois and Ryan M. Field and Frank A. Fishburn and Andrew Gundran and Wilson C. Ho and Sami Jawhar and Julian Kates‐Harbeck and Zahra M. Aghajan and Naomi Miller and Katherine L. Perdue and Jake Phillips and Wesley C. Ryan and Mahdi Shafiei and Felix Scholkmann and Moriah Taylor},
  title = {{Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS}},
  booktitle = {Scientific},
  year = {2023},
  doi = {10.1038/s41598-023-38258-8},
}
Figure